Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 206792, held by Novel Labs Inc. Desoximetasone.
As of Nov 15, 2026, ANDA 206792 (Desoximetasone), held by Novel Labs Inc, was first approved by FDA on May 10, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 10, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · ointment;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
